The potential vaccine, dubbed BBIBP-CorV, is being developed by the Beijing Institute of Biological Products, a subsidiary of China National Biotec Group (CNBG).
Two injections of BBIBP-CorV at three different doses generated antibodies in all recipients of each group, including older participants, although the data does not prove the vaccine is efficacious, researchers at the CNBG subsidiary, Chinese disease control authorities and other research institutes said in the paper.
Apart from BBIBP-CorV, CNBG, a unit of state-owned China National Pharmaceutical Group (Sinopharm), has another similar candidate developed by a different subsidiary which is also being tested overseas in Phase III trials and used in China's emergency use programme.
UK
Australia
France
Germany
Russia
India
Canada